Wall Street equity research analysts tracking SOPHiA GENETICS (NASDAQ: SOPH) typically issue consensus ratings ranging from Hold to Moderate Buy, highlighting the long-term growth potential of its cloud-based healthcare analytics platform alongside near-term caution regarding operational cash burn and profitability timelines.